Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.
Recently, a clincial investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.
Highly respected by his peers, Dr. Stock was named to the list of U.S. News "Top Doctors," which denotes the top 10% of physicians within a region practicing a given specialty. He is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies. Dr. Stock specializes in liver, kidney and pancreas transplantation.
Dr. Stock's current basic science research interests include the induction of transplantation tolerance to block both alloimmunity as well as recurrent autoimmunity following pancreatic islet transplantation. Rresults from these studies can be directly applied to the protection of human pancreatic islets following transplantation into diabetic recipients.
Dr. Stock also conducts research on the safety and efficacy of solid organ transplantation in people with HIV. With the advent of highly active anti-retroviral therapy (HAART), people are no longer dying from progression of HIV to AIDS, but rather as result of the co-morbidities associated with HIV infection.
Dr. Stock is Principal Investigator on an NIH-sponsored national multicenter trial examining the impact of HIV on graft survival, the impact of immunosuppression of the immune response against HIV and co-pathogens (HBV, HCV, HPV, CMV, EBV), and the pharmacokinetic interactions of immunosuppressive agents and HAART therapy. Recently, the group reported in the New England Journal of Medicine (see below), that HIV kidney transplant recipients have survival similar to other patients undergoing kidney transplants. These studies will have a direct impact on the management of a rapidly increasing number of HIV-infected patients with end stage liver disease secondary to hepatitis B and C co-infection.
A clincial investigation by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D. led to the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients. Click here to enlarge image.
"The sun wasn't up at 5 o'clock Wednesday
morning, but a new day had already dawned for Matthew
Ouimet. Matthew, a 2-year-old
Antioch boy who had waited 15 months for a life-sustaining kidney
and liver transplant, had his new organs. Dr. John
Roberts took the lead on the liver transplant, and Dr.
Peter Stock, who handled the kidney procedure in a 12-hour
surgery that began around 6 p.m. Tuesday, delivered the good news
to parents Kristi and Kelly Ouimet and a half-dozen family members
who spent the night at UCSF Benioff Children's
Hospital. "They look pretty good," Stock said of the
transplanted organs. "There were no problems. He's very
Excerpts from story at Silicon Valley MercuryNews.com
In its most recent survey, U.S. News in collaboration with Castle Connolly Medical Ltd. listed twenty-five (25) surgeons in the UCSF Department of Surgery, nearly one-third (1/3) of the clinical faculty, on the list of U.S. News "Top Doctors". The list, compiled from the opinion of colleagues, denotes the top 10% of physicians within a region practicing a given specialty. Fifteen of the 25 department surgeons were also named by their peers to the list of America's Top Doctors (ATD), a distinction reserved for the top 1% of physicians in the nation for that specialty. The listings are published online at U.S. News. The group rankings are intended to guide patients in selecting a doctor and physicians in making specialty referrals.
Last year, a team led by Dr. Peter Stock of UCSF reported on results from a large multicenter study testing the safety and feasibility of transplanting kidneys where both the donor and recipients were infected with HIV, the virus that causes AIDS. The results, reported in the New England Journal of Medicine, showed that the recipients survived nearly as long as non-HIV infected recipients of kidney transplants. As a result of the Stock-led trial, and a just-published paper from Johns Hopkins projecting that 500 to 600 H.I.V.-infected livers and kidneys would become available each year if the ban were repealed, the paradigm appears to be changing. Federal health agencies, including the CDC, are now urging, as reported by the N.Y. Times in today's editions, that the absolute ban on transplanting H.I.V.-positive organs be lifted.
"Previously, Uruguay had tried to go it alone, but high mortality rates soon caused doctors to shut the program down. After their initial visit, the UCSF transplant team, including anesthesiologist Claus Niemann, MD (pictured first), and surgeons Ryutaro Hirose, MD (pictured second), and Peter Stock, MD, PhD, (pictured third) continued to consult with the team in Uruguay, guiding them through everything from patient selection procedures to the use of immunosuppressive medications following surgery. When it came time for Uruguayan doctors to conduct their first liver transplant since revamping the program, UCSF doctors oversaw the operation by dialing in via Skype."
"People infected with the AIDS virus can safely receive a kidney transplant, researchers reported on Wednesday. The finding, published in Thursday's New England Journal of Medicine, is good news for people with HIV who are more prone to kidney disease, in part because of the drugs they must take to stay healthy. Before drug cocktails turned HIV from a death sentence to a chronic condition, patients were not eligible to receive a kidney. But now they can. 'Patient and graft survival are really pretty good and it approximates the general population,' Dr. Peter Stock of the University of California San Francisco, who led the study, said in a telephone interview."